1. Aluwini S, Pos F, Schimmel E, van Lin E, Krol S, van der Toorn PP, de Jager H, Dirkx M, Alemayehu WG, Heijmen B, Incrocci L (2015) Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. Lancet Oncol 16:274–283. https://doi.org/10.1016/S1470-2045(14)70482-6
2. Aluwini S, Pos F, Schimmel E, Krol S, van der Toorn PP, de Jager H, Alemayehu WG, Heemsbergen W, Heijmen B, Incrocci L (2016) Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncol 17:464–474. https://doi.org/10.1016/S1470-2045(15)00567-7
3. Azzam EI, de Toledo SM, Gooding T, Little JB (1998) Intercellular communication is involved in the bystander regulation of gene expression in human cells exposed to very low fluences of alpha particles. Radiat Res 150:497–504. https://doi.org/10.2307/3579865
4. Bazinet A, Zorn KC, Taussky D, Delouya G, Liberman D (2020) Favorable preservation of erectile function after prostate brachytherapy for localized prostate cancer. Brachytherapy 19:222–227. https://doi.org/10.1016/j.brachy.2019.11.003
5. Berger AM, Mooney K, Banerjee C, Breitbart WS, Carpenter KM, Chang Y, Cleeland C, Davis, Dest V, DuBenske LL, Escalante CP, Fernandez-Robles C, Garcia S, Jankowski C, Jatoi A, Kinczewski LE, Loggers ET, Mandrell B, McInnes S, Meyer F, Murphy BA, Palesh O, Patel H, Riba MB, Rohal A, Rugo HS, Salvador C, Wagner-Johnston N, Walter M, Webb JA, Bergman MA, Darlow S, Hochstetler C (2020) National comprehensive cancer network. Cancer-Related Fatigue, Version 2.2020. http://www.NCCN.org/professionals/physician_gls/pdf/fatigue.pdf. Zugegriffen am 18.11.2020